Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
EGFR is a protein kinase whose aberrant activity is frequently involved in the development of non-small lung cancer (NSCLC) drug resistant forms. The allosteric inhibition of this enzyme is currently one among the most attractive approaches to design and develop anticancer drugs. In a previous study...
Saved in:
Main Authors: | Francesca Foschi (Author), Annachiara Tinivella (Author), Valentina Crippa (Author), Luca Pinzi (Author), Luca Mologni (Author), Daniele Passarella (Author), Giulio Rastelli (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease
by: Luca Pinzi, et al.
Published: (2021) -
Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
by: Mahmoud G. Abo Al-Hamd, et al.
Published: (2023) -
AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021) -
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
by: Muammar Fawwaz, et al.
Published: (2021) -
Design and Synthesis of New Hydantoin Acetanilide Derivatives as Anti-NSCLC Targeting EGFR<sup>L858R/T790M</sup> Mutations
by: Moamen A. Hassanin, et al.
Published: (2022)